Dose effect of influenza vaccine on protection against laboratory-confirmed influenza illness among children aged 6 months to 8 years of age in southern China, 2013/14–2015/16 seasons: a matched case–control study

Fu, Chuanxi; Greene, Carolyn M.; He, Qing; Liao, Ying; Wan, Yanmin; Shen, Jichuan; Rong, Chao; Zhou, Suizan

doi:10.1080/21645515.2019.1662267

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 , 18 The national pharmacopoeia of China recommends that children aged <3 years receive the 0.25 mL dose (containing 7.5 μg hemagglutinin per virus strain) of any influenza vaccine, while globally a 0.5 mL dose (containing 15 μg hemagglutinin per virus strain) of influenza vaccine is more widely recommended in this age group. 19 Our study showed that the safety profiles of Shz QIV (0.25 mL) and Shz QIV (0.5 mL) were similar after the first and the second injections in those aged 6–35 months, suggesting that the increased dose does not compromise safety in this age group. HAI antibody responses were slightly higher for Shz QIV (0.5 mL) than Shz QIV (0.25 mL) and non-inferiority of the 0.25 mL dose for the B/Victoria-like strain was not shown.…”

Section: Discussionmentioning

confidence: 50%

“…In those who were previously unvaccinated, the second dose of Shz QIV elicited higher HAI antibody responses than after the first, suggesting that a schedule of two doses, 4 weeks apart would be more appropriate for previously unvaccinated children in this age range. However, the Chinese national pharmacopoeia recommends that children aged 3–8 years receive one dose irrespective of previous influenza vaccination history, 19 which is inconsistent with guidelines by the Chinese Center for Disease Control and Prevention, 22 and those by the World Health Organization 23 and the Advisory Committee on Immunization Practices (ACIP) in the USA. 24 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Liu

Park

Xia

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A quadrivalent, split-virion influenza vaccine (Shz QIV), containing two influenza A strains, and both B lineages strains, has been developed in China. We report the safety and immunogenicity of Shz QIV in two studies: a single-center, phase I, open-label, safety trial (n = 101) and a multicenter, phase III, observer-blind, randomized, safety and immunogenicity trial (n = 7,106) comparing Shz QIV with two trivalent influenza vaccines (Shz TIVs; one containing a B/Victoria-like strain and the other a B/Yamagata-like strain). Participants received one dose of Shz QIV (0.5 mL), except children aged 6 months to 8 years who received one or two doses (0.25 mL or 0.5 mL) depending on previous influenza vaccination. The Shz TIV groups received one or two (0.25 mL) doses depending on previous influenza vaccination (ages 6–35 months) or a single (0.5 mL) dose (ages ≥3 years). Immunogenicity was assessed at baseline and 28 days after the last dose, with safety assessed through to 6 months. The primary objective was to demonstrate the non-inferiority of antibody responses to Shz QIV (0.25 mL and 0.5 mL) versus Shz TIVs for each strain in ages 6–35 months and ≥3 years. Overall, Shz QIV was well tolerated, and showed similar safety to the Shz TIVs. Shz QIV (0.5 mL) induced non-inferior antibody responses to all antigens versus Shz TIV, with superiority demonstrated to the non-corresponding B strain in each TIV. Shz QIV (0.25 mL) non-inferiority in those aged 6–35 months was demonstrated for both A strains and the B/Yamagata-like strain, but not the B/Victoria-like strain. In summary, Shz QIV (0.5 mL) is immunogenic and has a good safety profile. WHO Universal Trial Numbers (UTNs) U1111-1174-4615 and U1111-1174-4698 ClinicalTrials.gov NCT04210349 and NCT03430089

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Liu

Park

Xia

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…29 In the 2013-2014, 2014-2015, and 2015-2016 seasons, vaccination rates for children 6-96 months old were 18.0%, 13.5%, and 10.0%, respectively. 30 Our study then showed a 1.0% rate in the 2019-2020 season. Growing vaccine hesitancy 31 has prevented reaching and maintaining high vaccination coverage.…”

Section: Discussionmentioning

confidence: 50%

Effectiveness of seasonal influenza vaccine against influenza outbreaks in schools in Guangzhou, China

Xiao

et al. 2023

Preprint

View full text Add to dashboard Cite

Influenza-like illness (ILI) outbreaks mainly occurred in schools. And annually reformulated composition of influenza vaccines makes it necessary to estimate the effectiveness of the seasonal influenza vaccine. We aimed to estimate the effectiveness of the seasonal influenza vaccine against influenza outbreaks in schools. Methods This was a matched case-control study estimating the effectiveness of the influenza vaccine in preventing school influenza outbreaks. The laboratory-confirmed cases of influenza in school children were paired by the random sample of asymptomatic classmates by sex and age during the 2019–2020 influenza season. Influenza vaccine effectiveness was estimated using a conditional logistic regression model. Results During the 2019–2020 influenza season, 503 paired samples of laboratory-confirmed influenza cases and asymptomatic controls were enrolled. The influenza vaccination rates for cases and controls were 0.40% and 1.59%, respectively. The vaccine effectiveness against influenza outbreaks in schools was 74.35% (95% CI: 5.39–122.00) during the 2019–2020 season. Conclusions No significant vaccine effectiveness was observed during influenza outbreaks in schools during the 2019–2020 influenza season because of the low vaccination rate. Efforts should be made to increase vaccination coverage among students.

show abstract

“…The search terms identified 1408 studies from the six databases—282 from the Wanfang database, 472 from CNKI, 302 from VIP journal database, 282 from CBM, 130 from Web of Science, and 27 from PubMed. Our eligibility review identified 21 articles for including in the analyses [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ] ( Figure 1 ). The 21 eligible studies were conducted between the 2010–2011 influenza season and the 2017–2018 influenza season.…”

Section: Resultsmentioning

confidence: 99%

Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis

Yang

Zhao

et al. 2021

Vaccines

View full text Add to dashboard Cite

Influenza endangers human health but can be prevented in part by vaccination. Assessing influenza vaccine effectiveness (VE) provides scientific evidence for developing influenza vaccination policy. We conducted a systematic review and meta-analysis of studies that evaluated influenza VE in mainland China. We searched six relevant databases as of 30 August 2019 to identify studies and used Review Manager 5.3 software to analyze the included studies. The Newcastle–Ottawa scale was used to assess the risk of publication bias. We identified 1408 publications, and after removing duplicates and screening full texts, we included 21 studies in the analyses. Studies were conducted in Beijing, Guangzhou, Suzhou, and Zhejiang province from the 2010/11 influenza season through the 2017/18 influenza season. Overall influenza VE for laboratory confirmed influenza was 36% (95% CI: 25–46%). In the subgroup analysis, VE was 45% (95% CI: 18–64%) for children 6–35 months who received one dose of influenza vaccine, and 57% (95% CI: 50–64%) who received two doses. VE was 47% (95% CI: 39–54%) for children 6 months to 8 years, and 18% (95% CI: 0–33%) for adults ≥60 years. For inpatients, VE was 21% (95% CI: −11–44%). We conclude that influenza vaccines that were used in mainland China had a moderate effectiveness, with VE being higher among children than the elderly. Influenza VE should be continuously monitored in mainland China to provide evidence for policy making and improving uptake of the influenza vaccine.

show abstract

Dose effect of influenza vaccine on protection against laboratory-confirmed influenza illness among children aged 6 months to 8 years of age in southern China, 2013/14–2015/16 seasons: a matched case–control study

Cited by 6 publications

References 18 publications

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Effectiveness of seasonal influenza vaccine against influenza outbreaks in schools in Guangzhou, China

Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About